ContactContactFrançais
  • Home
  • News
  • Market Data
  • Participants
  • Émetteurs
  • Investisseurs
  • Education
  • Profil

Cookie

Notre site utilise des cookies. Cela nous permet d'optimiser votre expérience utilisateur. En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies. Vous trouverez de plus amples informations dans notre déclaration de confidentialité.

 
 

News

 

16.06.2017 Issuers

Idorsia lists on SIX Swiss Exchange

Stock exchange bell rings in the trading of the shares of Idorsia.

SIX Swiss Exchange is welcoming Idorsia Ltd. (IDIA), an additional company from the life sciences sector (listing video). Idorsia is a biopharmaceutical company created from the demerger of Actelion's drug discovery and early clinical pipeline business. The opening price was CHF 10.00. This corresponds to a market capitalization of CHF 1.073 billion. Idorsia shares will be listed in accordance with the International Reporting Standard and included in the SPI® as well as the SXI Life Sciences® and SXI Bio+Medtech® indices.

Chris Landis, Division CEO Swiss Exchange: «As the leading European stock exchange in the life sciences sector, we are delighted that Idorsia has decided to list its shares on SIX Swiss Exchange. Thanks to our leading position, listed companies benefit from a dynamic market environment and excellent visibility among specialist investors and the media. With Idorsia, we will have an additional company with comprehensive expertise and research in our life science peer universe.»



André Muller, CFO Idorsia, Jean-Paul Clozel, CEO Idorsia and
Andrew Weiss, Head of IR & Corporate Communications, Idorsia (f.l.)

All the ingredients for success

Headquartered in Switzerland Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. «The future for Idorsia is looking bright. Realizing our ambition to develop Idorsia into one of Europe's leading biopharmaceutical company, with a strong scientific core, certainly won't be an easy undertaking but we have all the ingredients for success», so Jean-Paul Clozel, CEO Idorsia. «The listing on SIX Swiss Exchange will support us, as it was the case for Actelion in the last 17 years.»

According to Jean-Paul Clozel, Idorsia has an experienced team with a proven track record, a full research and development pipeline, state-of-the-art research facilities and CHF 1 billion in cash at inception. He believes that these are crucial elements for transforming research and development into successful medicines.

Numerous benefits for equity issuers

A listing on SIX Swiss Exchange provides companies with access to strongly capitalized Swiss and international investors. In addition, we make things as simple as possible for them with first-class, needs-oriented services, allowing them to efficiently raising capital and therefore achieving sustainable growth. Our appeal extends far beyond the borders of Switzerland.

An overview and helpful information on all topics relevant to going public on SIX Swiss Exchange can be found in the comprehensive Going Public Guide or in the compact «IPO Guide Schweiz» (available only in German). Further information on our range of services for issuers can be found on our website.

Contact

Show all news